Several new biomarkers for atopic dermatitis have been identified that may serve as targets for future drugs, according to a research letter from Angelo Landriscina at Albert Einstein College of Medicine, New York, and his associates.

In a study of 40 biopsy specimens from patients with atopic dermatitis (AD) and 40 matched controls from banked abdominoplasty tissue, interleukin-2 was found to produce pruritus in all study subjects, but this process was accelerated in AD patients. The pruritigens in the arachidonic acid pathways, leukotriene B4 and 5-lipoxygenase, also were increased in AD patients. In addition, the investigators found increased matrix metalloproteinase (MMP)-7, a product of mast cell degradation. In AD, mast cells localize in the epidermis and are stimulated, releasing MMP-7. Finally, alpha-2 macroglobulin was significantly elevated in AD skin.

“Interestingly, all mediators investigated are inhibited by hypochlorous acid, formed when sodium hypochlorite (bleach) mixes with water at pH 5-7,” the investigators noted.

Find the full research letter in Journal of the American Academy of Dermatology ( doi:10.1016/j.jaad.2015.06.036 ).

lfranki@frontlinemedcom.com

Ads

You May Also Like

Moderate THST was most effective at treating thyroid cancer

Moderate thyroid hormone suppression therapy (THST) is associated with the best outcomes for patients ...

Ulcerative colitis is disabling over time

FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Between 70% and 80% of patients with ulcerative colitis ...